MDSpire - Summary
From the Journals

Fluvoxamine Reduces Long COVID Fatigue in Trial

A randomized, placebo-controlled trial found the selective serotonin reuptake inhibitor improved fatigue severity vs placebo, while metformin showed no evidence of benefit.

Share

The REVIVE-TOGETHER trial demonstrated that fluvoxamine significantly reduces fatigue severity in long COVID patients compared to a placebo, while metformin showed no benefit. Conducted across 22 outpatient sites in Brazil, the trial enrolled 399 patients with moderate to severe fatigue following SARS-CoV-2 infection. Results indicated that fluvoxamine provided sustained fatigue reduction and improved health-related quality of life, though metformin did not. The study emphasizes the need for further research to explore fluvoxamine's potential benefits in this population.

Original Source(s)

Fluvoxamine Reduces Long COVID Fatigue in Trial

  • by Kerri Miller

  • April 2, 2026

Related Content

Inside Access, Outside the Rules

Two federal cases highlight alleged misuse of professional roles in health care settings

Side Effects: Variety Is Overrated

The organ you forgot, the cells that age unevenly, the AI that admits ignorance, and the diet advice that sounds wrong but isn't: medicine's next moves are hiding in plain sight.

Tirzepatide Linked to Greater QoL Gains vs Dulaglutide

Both groups improved, with numerically larger gains in patient-reported outcomes following a switch to tirzepatide